Basal cell cancer treatment. Therapeutic experience with vismodegib therapy

Abstract

Most patients with basal cell cancer (BCC) can be cured if timely diagnosed. However approximately 1,3% of BCCs may develop into locally-advanced and sometimes even metastatic disease when local treatment options are limited and systemic therapy is warranted. Vismodegib was the first drug which demonstrated efficacy for the treatment of locally-advanced and metastatic BCC, inhibiting pathologically active Sonic Hedgehog (SHh) signaling pathway in tumor cells and preventing their uncontrolled proliferation.

Keywords

• basal cell cancer
• ptch
• vismodegib
• sonic hedgehog signaling pathway
• gorlin-goltz syndrome
• sonidegib